Preventing macrovascular complications of diabetes: where do we stand with glycemic control?

Author： Athyros Vasilios G   Tziomalos Konstantinos   Karagiannis Asterios   Mikhailidis Dimitri P  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.17, Iss.12, 2008-12, pp. : 1777-1779

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Editorial: Dietary Habits, Pharmacogenomics and Treatment of Diabetes and its Complications: Where do we Stand?

By  

Current Pharmaceutical Design, Vol. 20, Iss. 22, 2014-05 ,pp. : 3607-3609

Bentham Science Publishers

Access to resources Recommend Favorite

GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?

By  

Current Pharmaceutical Design, Vol. 21, Iss. 36, 2015-11 ,pp. : 5292-5298

Bentham Science Publishers

Access to resources Recommend Favorite

Statins in Heart Failure—Where Do We Stand?

By Lyons Kristopher   McVeigh Gary   Harbinson Mark  

Cardiovascular Drugs and Therapy, Vol. 25, Iss. 1, 2011-02 ,pp. : 99-104

Springer Publishing Company

Access to resources Recommend Favorite

Intelligent use of NSAIDs - where do we stand?

By Berger R.G.  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 1, 2001-01 ,pp. : 19-30

Informa Healthcare

Access to resources Recommend Favorite

Mucosal Vaccines: Where Do We Stand?

By  

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 20, 2013-10 ,pp. : 2609-2628

Bentham Science Publishers

Access to resources Recommend Favorite